-+ 0.00%
-+ 0.00%
-+ 0.00%

Foghorn reports preclinical data for SMARCA2 inhibitor FHD-909 in mouse models

PUBT·04/21/2026 20:07:00
Listen to the news
Foghorn reports preclinical data for SMARCA2 inhibitor FHD-909 in mouse models
  • Foghorn Therapeutics presented new preclinical data at 2026 AACR Annual Meeting on April 21, 2026, highlighting its selective SMARCA2 inhibitor FHD-909 (LY4050784).
  • Combination treatment of FHD-909 with an anti-PD-1 antibody produced complete, durable tumor regression in syngeneic mouse models, with evidence of anti-tumor immune memory.
  • Preclinical updates also showed selective CBP degrader FHT-171 delivered strong anti-tumor activity with favorable tolerability in models of heavily pretreated ER+ breast cancer.
  • Selective EP300 degrader data in multiple myeloma models indicated stronger efficacy with improved tolerability versus a clinical benchmark dual CBP/EP300 inhibitor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foghorn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211605PRIMZONEFULLFEED9693508) on April 21, 2026, and is solely responsible for the information contained therein.